Iovance Stock Surges on Unprecedented 50% ORR in First TIL Trial for Tough Sarcomas

Iovance Biotherapeutics shares soared after reporting a 50% response rate in the first TIL therapy trial for hard-to-treat soft tissue sarcomas and solid Q4/FY2025 results with 30% revenue growth.